(Q39317250)

English

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

0 references

0 references

0 references

author name string

Kei Matsueda

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Shigeru Harasawa

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Michio Hongo

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Nobuo Hiwatashi

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Daisuke Sasaki

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1202-1211

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The impact of irritable bowel syndrome on health-related quality of life

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Sex-related differences in IBS patients: central processing of visceral stimuli

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Review article: intestinal serotonin signalling in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Is there a SERT-ain association with IBS?

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization

1 reference

https://api.crossref.org/works/10.1080%2F00365520802240255

21 January 2018

Identifiers

10.1080/00365520802240255

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39317250&oldid=1967514427"